Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) P/B ratio
As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a P/B ratio of 24.2×. Over the past ten years it has ranged from 0.0× (June 2018) to 56.0× (December 2024); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2022 | 2.2× | (58.59%) |
| FY2021 | 5.3× | (7.34%) |
| FY2020 | 5.7× | 77.92% |
| FY2019 | 3.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Mar 2022 | 2.8× | (46.82%) |
| Dec 2021 | 5.3× | (18.07%) |
| Sep 2021 | 6.5× | 32.55% |
| Jun 2021 | 4.9× | (36.31%) |
| 9 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | n/m |
| CGON CG Oncology, Inc. compare | 5.6× |
| MANE Veradermics Incorporated compare | 6.4× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 7.5× |
| IMVT Immunovant, Inc. compare | 8.0× |
| COGT Cogent Biosciences, Inc. compare | 10.9× |
| ERAS Erasca, Inc. compare | 11.5× |
| SRRK Scholar Rock Holding Corporation | 23.5× |
| KOD Kodiak Sciences Inc. compare | 94.0× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement